Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

Ceftolozane/tazobactam, which is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, advanced into Phase 3 trials in July 2011…

Cubicin
Entereg
Dificid

Upcoming Events

News & Press

19 May

Cubist Achieves Top Biotech Ranking in Globe 100 List

Number Six Overall Ranking Reinforces Employee Dedication to Addressing Unmet Need in Acute Medical Care

Careers at Cubist

Keith

Meet Keith

CBM, Birmingham West Region

A Clinical Business Manager in the Birmingham West region, Keith sees himself as one of the “faces of Cubist” with the…

Current Opportunities

View our Careers page to see all current opportunities with Cubist.

Community Outreach

Science Education Leadership Award

Cubist Science Education Leadership Award Program: Recognizing Innovative Teachers Across New England

Investor Center

Cubist Pharmaceuticals $56.11 +0.65
CBST (NASDAQ) UPD: 4:00pm

Investor Resources